Department of Thyroid and Breast Surgery, Linyi People's Hospital, Linyi, Shandong, China.
Eur Rev Med Pharmacol Sci. 2017 Oct;21(17):3794-3800.
MiRNAs are small, noncoding RNA molecules that serve as important regulators of cancer-related processes. Abnormal expression of miR-577 has been found in several tumors. However, the expression pattern and biological function of miR-577 in progression of papillary thyroid cancer (PTC) remain unknown. This study is aimed to determine its expression pattern and explore the function underlying the mechanism of miR-577 in PTC.
Using quantitative RT-PCR, we detected miR-577 expression in PTC cell lines and primary tumor tissues. MTT assay and colony formation were performed to measure the viabilities of tumor cells. Transwell invasion and migration assays were used to test the invasion and migration of PTC cells transfected with miR-577 mimic. TargetScan, miRanda and PicTar were used to analyze whether sphingosine kinase 2 (SphK2) was a potential target gene. Next, the direct target gene of miR-577 was also identified by luciferase reporter assays and Western blot analysis.
The results showed that miR-577 was significantly downregulated in PTC tissues and cell lines. The up-regulation of miR-577 inhibited the proliferation, migration and invasion of PTC cells in vitro. Furthermore, bioinformatics analysis indicated that SphK2 was a putative target of miR-577. A luciferase reporter assay further confirmed that SphK2 was a direct target of miR-577. The results of Western blot indicated that the expression level of miR-577 was negatively correlated with the expression level of SphK2 in PTC tissues. In addition, knockdown of SphK2 significantly suppressed PTC cells proliferation, migration and invasion.
Our findings indicate that miR-577 is a potential tumor suppressor in PTC by targeting SphK2, and may be a potential therapeutic target in PTC.
miRNAs 是一种小的非编码 RNA 分子,作为癌症相关过程的重要调节剂。已经在几种肿瘤中发现 miR-577 的异常表达。然而,miR-577 在甲状腺乳头状癌(PTC)进展中的表达模式和生物学功能尚不清楚。本研究旨在确定其表达模式,并探讨 miR-577 在 PTC 中的作用机制。
使用定量 RT-PCR 检测 PTC 细胞系和原发肿瘤组织中 miR-577 的表达。MTT 检测和集落形成实验用于测量肿瘤细胞的活力。Transwell 侵袭和迁移实验用于检测转染 miR-577 模拟物的 PTC 细胞的侵袭和迁移。TargetScan、miRanda 和 PicTar 用于分析 SphK2 是否是潜在的靶基因。接下来,通过荧光素酶报告基因检测和 Western blot 分析确定 miR-577 的直接靶基因。
结果表明,miR-577 在 PTC 组织和细胞系中显著下调。miR-577 的上调抑制了 PTC 细胞的体外增殖、迁移和侵袭。此外,生物信息学分析表明 SphK2 是 miR-577 的一个潜在靶基因。荧光素酶报告基因检测进一步证实 SphK2 是 miR-577 的直接靶基因。Western blot 结果表明,miR-577 在 PTC 组织中的表达水平与 SphK2 的表达水平呈负相关。此外,SphK2 的敲低显著抑制了 PTC 细胞的增殖、迁移和侵袭。
我们的研究结果表明,miR-577 通过靶向 SphK2 作为 PTC 的潜在肿瘤抑制因子,可能成为 PTC 的潜在治疗靶点。